Expert panel recommendations: With combination therapy of CDK4/6 inhibitors plus endocrine therapy becoming the first‐line treatment of HR‐positive/HER2‐negative advanced breast cancer now, in general, CDK4/6 inhibitor plus fulvestrant is also administered in patients who failed AI therapy. The gene discussed is ERBB2; the disease is breast carcinoma.